Does OMOP CDM Conversion Improve Cross-Country Comparability of Real-World Data? A Benchmark Study in Breast Cancer and Amyotrophic Lateral Sclerosis

09 Jul 20264 min read1 viewsVerified Feed

GIST (Key Takeaways)

Background: Real-world data (RWD) from different countries are increasingly used to support regulatory, health technology assessment (HTA), and population-level evidence generation. However, cross-country analyses are challenged by differences in data provenance, healthcare systems, coding practices, completeness, and clinical workflows.
The Observational Medical Outcomes Partnership (OMOP) common data model (CDM) is widely used to harmonise heterogeneous RWD sources, but its ability to improve comparability of downstream epidemiological analyses relative to native source data across countries requires empirical evaluation. Methods: We examined RWD from Denmark, Finland and Portugal in their ability to capture epidemiology of female breast cancer (BC) and amyotrophic lateral sclerosis (ALS), exemplifying, respectively, a common disease with established treatment modalities and high survival and a rare fatal disease with scarce treatment options.
To enable head-to-head comparison on a semantic level, data were mapped to the OMOP CDM. Data in the native format were used for comparison.
In a downstream analysis, we examined disease epidemiology, patient characteristics, treatment, and survival.